Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network.

Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network.

Publication date: Jun 26, 2019

To report efficacy and tolerance of nivolumab or pembrolizumab, PD-1 inhibitors, in people living with HIV (PLWHIV) and cancer.

Series of PLWHIV cancer patients treated with anti-PD1 agents in real life clinical practice.

From May 2014 to January 2019, 575 HIV infected patients have been discussed in the French CANCERVIH national multidisciplinary board and included in the network database. 23 patients were treated with ICI in daily practice. We report the demographic characteristics, CD4 T cell counts, HIV viral loads, safety and efficacy data of these 23 PLWHIV treated in routine practice with nivolumab or pembrolizumab for non-small cell lung cancer (n = 21), melanoma (n = 1) and head and neck cancer (n = 1) retrospectively collected from the database CANCERVIH network. The median CD4 T cell count at treatment initiation was 370/mm (IQR: 125-1485). HIV viral load was undetectable in all patients.

As of 29 April 2019, with a median follow-up of 10.8 months (2.0-27.7), the median number of injections was 6 (IQR: 4-18). Only two grade 3 adverse reactions were reported (no toxic deaths or immune-related deaths). Among the 23 patients, a partial response was observed in 5 patients (22%), a stabilization for 5 (22%) and a progression in 13 (57%). Only one patient experienced a positive HIV viral load, but this occurred following ART interruption.

Treatment with PD-1 inhibitors seems to have an efficacy signal and be well tolerated in PLWHIV, including impact on CD4 lymphocyte count and HIV load, that should be monitored during treatment course (regarding real-life experience).

Spano, J.P., Veyri, M., Gobert, A., Guihot, A., Perr’e, P., Kerjouan, M., Brosseau, S., Cloarec, N., Montaudie, H., Helissey, C., Flament, T., , Gounant, Lavol’e, A., , Poizot-Martin, and Katlama, C. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network. 23205. 2019 AIDS.

Concepts Keywords
AIDS CD4
Cancer Treatment as prevention
CD4 Management of HIV/AIDS
Demographic Medicine
French Hepatotoxins
HIV Branches of biology
ICI Prevention of HIV/AIDS
Immunotherapy Medical specialties
IQR AIDS
Life Experience Immunotherapy
Lung Melanoma
Lymphocyte HIV
Melanoma Cancer
Viral
Viral Load

Semantics

Type Source Name
gene UNIPROT IMPACT
gene UNIPROT AGRP
gene UNIPROT ARTN
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
disease MESH viral load
disease DOID head and neck cancer
disease MESH head and neck cancer
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
pathway BSID Non-small cell lung cancer
disease DOID non-small cell lung cancer
disease MESH non-small cell lung cancer
gene UNIPROT CD4
gene UNIPROT SNCA
gene UNIPROT SPATA2
gene UNIPROT PDCD1
gene UNIPROT RPL17
drug DRUGBANK Nivolumab
drug DRUGBANK Pembrolizumab
disease MESH life experience
disease DOID cancer
disease MESH cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *